Polyenes

• 

  Subject Areas on Research

  • 2-Azadienes as Reagents for Preparing Chiral Amines: Synthesis of 1,2-Amino Tertiary Alcohols by Cu-Catalyzed Enantioselective Reductive Couplings with Ketones. 
  • Adenylate cyclase-coupled beta adrenergic receptors effect of membrane lipid-perturbing agents on receptor binding and enzyme stimulation by catecholamines. 
  • Antifungals in Clinical Use and the Pipeline. 
  • Calcineurin is required for virulence of Cryptococcus neoformans. 
  • Copper-Catalyzed Three-Component Aminofluorination of Alkenes and 1,3-Dienes: Direct Entry to Diverse β-Fluoroalkylamines. 
  • Current options in antifungal pharmacotherapy. 
  • Disruption of the gene encoding the mitogen-regulated translational modulator PHAS-I in mice. 
  • Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 
  • Exploring chemical space with discrete, gradient, and hybrid optimization methods. 
  • Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. 
  • FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. 
  • Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. 
  • Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors. 
  • Letter: Polyene antibiotics. VI. The structures of dermostatins A and B. 
  • Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast. 
  • Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 
  • New facets of antifungal therapy. 
  • Pharmacokinetics of antifungal agents in children. 
  • Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 
  • Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. 
  • Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway. 
  • Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats. 
  • Regulatory mechanisms of a chemoattractant receptor on human polymorphonuclear leukocytes. 
  • Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. 
  • TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. 
  • Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 
  • The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. 
  • The structures of dermostatins A and B 1,2. 
  • Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement.